QuantumMike

@IcnpcS @AnnMill28215764 @DrMakaryFDA You list side effects that are caused by the delivery mechanism not ANKTIVA. Catheter delivery cause the urinary tract infections. Your assessment is disingenuous at best

ImmunityBio's so-called "breakthrough" immunotherapy for bladder cancer. This drug is a masterclass in pharmaceutical failure dressed up as innovation. Approved by the FDA in 2024 for a narrow slice of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), it's been plagued by regulatory rejections, questionable efficacy claims, and a side-effect profile that makes you wonder if the cure is worse than the disease. Critics in the medical community have rightly slammed it for marketing that wildly outpaces the actual science—founder Patrick Soon-Shiong's bombastic promotions feel like snake oil salesmanship, promising the moon while delivering a pebble. newsnationnow.com +1 First off, the FDA has repeatedly slapped down attempts to expand its use, exposing the drug's weak foundations. In May 2025, the agency issued a flat-out Refusal to File (RTF) for a supplemental application to include papillary NMIBC without CIS, calling the data insufficient despite ImmunityBio's whiny protests that it contradicted earlier guidance. The company threw a public tantrum, demanding urgent meetings and accusing the FDA of "confounding inconsistency"—as if regulators are the problem, not the flimsy single-arm trial (QUILT-3.032) that's essentially the same dataset they used for the initial approval. Even former FDA officials like Rachel Sherman piled on in press releases, but it reeks of desperation: if your drug is so revolutionary, why can't it clear basic hurdles without begging and blaming? pharmexec.com +4 And the data? Laughable. In trials, it boasts about reversing lymphopenia or extending survival in tough cases like glioblastoma or NSCLC, but dig deeper: median overall survival "not yet reached" in small, cherry-picked groups sounds impressive until you realize it's often in patients who've already failed everything else, with no randomized controls to prove it's not just placebo or selection bias. The FDA called out these claims as potentially "false or misleading," especially when compared to giants like Keytruda, which got broader approvals on stronger evidence. Soon-Shiong's rants about double standards just highlight Anktiva's inferiority—it's not a chemo-free miracle; it's a niche player struggling to prove it's better than existing options. Side effects? Brutal for something that's supposed to be "manageable." Patients report urinary tract infections, skyrocketing potassium levels, musculoskeletal pain, chills, and fever—hardly the gentle immune boost hyped in press releases. Real-world use might amplify these, especially since trials overlook lymphopenia as a treatment side effect from standards like chemo or radiation. And with only 7% cystectomy rate in one follow-up? That's cherry-picking; broader adoption could reveal it's no bladder-sparer.

FDA is moving with unprecedented agility. Today we approved a multiple myeloma drug just 55 days after the application was filed. And last week’s approval (a major leap forward) was approved in 44 days. If a trial result shows immediate promise for many Americans, why wait?

@omphalos007 @DrMakaryFDA T cells and NK cells are dangerous? Dude you are the retard.

@DrMakaryFDA Don’t listen to all the $IBRXtards on this post - Anktiva is dangerous and should be pulled from the market

@DrPatrick @PeterPitts It’s time to play the Trump card. Trump is not going to say “no” to a cancer cure moment for his administration.

How do you defend a "no" to access for patients desperately seeking treatment, when the package insert affirms the mechanism that Anktiva activates T cells and NK cells? @PeterPitts provides the amazing truthful response that there is no reason. He highlights the mechanism of action in the package insert already approved. Peter also provides insight into the inconsistencies at the FDA when dealing with large pharma regarding approval with single arm trials versus biotech companies with a mission to cure cancer.

@reddit_lies Will this be the next mass psychosis?

A 22 year old Redditor claims he was approved for MAID when he was 19 because he has chronic BPD, autism, and depression. He will pass away in 5 days.

@farzyness Physical AI will need solid state batteries

What are the newest and biggest industries that appear when you have very cheap energy, robotic labor, and intelligence?

@gregtaniguchi @farzyness He was born there and has family there, he is also an Ivy League graduate and respected professor of finance. Take it as anecdotal but dont overreact like a retard

Yeah, I bet you also have a black friend that you cite having for all your anecdotal opinions. Also, throw in a Ukrainian friend who says “Ukrainians all love Russia.” The lies you put out is a reflection of you, and you could have asked Grok, but you don’t go by facts. Reunification for most Taiwanese is in the minority, 10%.

This is pretty obvious IMO.

@gregtaniguchi @farzyness My friend was born in Taiwan and visits family frequently tells me this

@QuantumMike1 @farzyness No they don’t, you gweilo have no clue

@SaccoFinancial The SLDP JV with Ford expired last year. Ford sold their stake in SLDP in July 2025.

QuantumScape $QS Deep Dive 👇 QuantumScape ($QS): The Solid-State Battery Bet Explained youtu.be/GHv_F00BSec

@SawyerMerritt History is repeating. City dwellers preferred the streets filled with horse shit, urine and disease instead of using cars.

NEWS: New York Governor Kathy Hochul has pulled a proposal that would have allowed for commercial robotaxi services outside New York City. The proposal, which Hochul had included in her budget proposal last month, would have allowed autonomous-vehicle companies such as Waymo to apply for permission to pilot their services without human operators in the vehicle. “Based on conversations with stakeholders, including in the legislature, it was clear that the support was not there to advance this proposal,” said Sean Butler, a Hochul spokesperson. Waymo said in a statement to Bloomberg that it was “disappointed” by the governor’s decision. “We’re committed to bringing our service to New York and will work with the state legislature to advance this issue.” bloomberg.com/news/articles/…

@SawyerMerritt Any indication of the door being able to close automatically? I read that Waymo hires DoorDash to close for an $11 fee

NEWS: Tesla has shared a new photo of the first Cybercab off the Giga Texas production line. Volume production is on track to start in April. Just 6-9 weeks away!

@david1901238626 OEMs have realized that the EV adoption needle will not move with crappy Li ion tech. Moves are being made to pivot to more advanced batteries

@david1901238626 Will take advances in battery tech for mass EV adoption to occur

@BatteryBulletin no specs for the sulfide SSB?

BYD breaks ground with solid-state battery and 10,000-cycle sodium tech power 2027 EVs share.google/hGRuenWYymlS1a…

@LLBiggers You are part of a growing trend of people realizing they got caught up in carefully crafted propaganda. Takes great strength and courage to come out publicly. I greatly admire you

The facts I learned that made me stop fearing climate change. 1. Deaths from natural disasters are down 95%. 2. 10x more people die from cold than from heat. 3. Global greening has increased. 4. Growers add up to 1,500 ppm of CO2 to their greenhouses. 5. Extreme weather has not gotten worse.

@chan2pa With Corning using their R2R Ribbon tech alongside Cobra fast sintering, scalability is solved

Despite the upcoming inauguration of the Eagle Line in February, the QuantumScape stock price keeps sliding. While there are concerns or doubts regarding their scalability in the market, I believe their underlying tech is still solid and compelling. Decided to add to my position today.

$QS After the recent AI software dump, it’s obvious the market will turn to physical manifestations of anything AI related. Investors will soon realize SSB is required for that evolution. The timing and position of QS is perfection. Keep until $500 to $1,000.

@david1901238626 No chemistry specs? No performance specs?

@ironmantimholme @demishassabis AGI is the pathway where all knowledge becomes free with no more secrets. All battery companies will have a level playing field for material knowledge. Winning will come down to economics.

@demishassabis wants to build models to develop better materials, for example to make better batteries. A 10x bigger unlock for battery development: to model the processes to make those materials - to the right scale, throughput, quality, yield, and cost. youtube.com/watch?v=PqVbyp…

@berriman_dave @alanvibe @elonmusk @politicshome So glad we have you to determine who uses what platform.

@alanvibe @elonmusk @politicshome So what? Government wants to shut down platform full of fascist cunt bots trying to destroy democracy. Yeah, I'll vote for that.

Wow: Leaked WhatsApp messages show Labour MPs urging govt to leave X, arguing that it should "show direction to others in the UK" The MPs said X owner @elonmusk is "fascist" and that the platform's AI tool, Grok, had put "children in harm's way"@politicshome With Labour MPs complaining about being used to make statements o @x